TIAA CREF Investment Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

TIAA CREF Investment Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-29,803	Closed	-$259K	–	3137
2018 Q1	$259K	Buy	29,803 +867	+3%	+$9.35K	﹤0.01%	2934
2017 Q4	$362K	Sell	28,936 -3,027	-9%	-$34.7K	﹤0.01%	2896
2017 Q3	$267K	Buy	31,963 +1,588	+5%	+$16.8K	﹤0.01%	3013
2017 Q2	$515K	Buy	+30,375	New	+$604K	﹤0.01%	2859
2016 Q2	–	Sell	-7,863	Closed	-$74K	–	3204
2016 Q1	$74K	Hold	7,863	–	–	﹤0.01%	3045
2015 Q4	$79K	Buy	+7,863	New	+$104K	﹤0.01%	3118

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FTIOP

Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TIAA CREF Investment Management's ZYNE Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2018, closing a stake of 29,803 shares — an estimated $259K sold.

TIAA CREF Investment Management first reported a position in ZYNE in Q4 2015 and held it in 6 quarters. The position peaked at $515K in Q2 2017. 59 funds tracked by Wall St. Rank hold ZYNE as of Q2 2018.

TIAA CREF Investment Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2018 after selling out during the quarter.
TIAA CREF Investment Management sold 29,803 Zynerba Pharmaceuticals, Inc shares in Q2 2018, an estimated $259K.
TIAA CREF Investment Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 6 quarters.
TIAA CREF Investment Management's Zynerba Pharmaceuticals, Inc position peaked at $515K in Q2 2017.
59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.